

Special Issue

Discovery of Novel Antidepressants and Anxiolytics

Message from the Guest Editors

Depression and anxiety are common psychiatric illnesses of global impact. Novel therapeutics are desirable among patients who continue to experience delayed or low responses, adverse effects, and unsatisfactory remission rates with the available drugs. Understanding the complex neurobiology of these psychiatric illnesses is among the prerequisites to the comprehensive assessments of biomarkers or molecular targets, pharmacokinetics, and the clinical efficacy, safety, acceptability, and tolerability of novel antidepressants and anxiolytics. This Special Issue accepts contributions covering new compound/drug candidates, research results, current understandings of depression and anxiety, and updates on pharmacotherapy options and other related topics.

Guest Editors

Prof. Dr. James Oluwagbamigbe Fajemiroye

Department of Pharmacology, Institute of Biological Sciences, Federal University of Goiás, Goiânia, Brazil

Dr. Gunnar P. H. Dietz

University of Göttingen Medical School, Göttingen, Germany

Deadline for manuscript submissions

25 November 2025



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/204419

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)